Cinnagen
Tel Aviv, Israel· Est.
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
Rare DiseasesOncologyImmunology
Technology Platform
A proprietary self‑amplifying mRNA (saRNA) platform combined with next‑generation lipid nanoparticle delivery for high‑potency, low‑dose protein expression.
Opportunities
Successful early‑phase data could unlock partnerships with large pharma and expand the platform into additional rare diseases and oncology indications.
Risk Factors
Technical uncertainty around long‑term safety of self‑amplifying mRNA and the need for substantial capital to advance multiple candidates through late‑stage trials.
Competitive Landscape
Cinnagen competes with mRNA leaders such as Moderna and BioNTech, but differentiates through its self‑amplifying approach that promises lower dosing and manufacturing cost.